Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Glioma Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

10 recruiting trials for Glioma. Eligibility criteria explained in plain English.

TrialFinderData lists 10 Glioma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 60% (3 studies); the largest phase groups are Phase 1: 3, Phase 4: 1, Phase 1 / Phase 2: 1.

Research is led by Pfizer (2), Rigel Pharmaceuticals (1), Plus Therapeutics (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is PF-07799933 (drug, 2 trials), followed by binimetinib, cetuximab.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
0
Phase 3 Trials
9
Sponsors

Track Glioma trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT05355701

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other...

Sponsor: PfizerEnrolling: 26720 locations
RECRUITINGPhase 4NCT07486713

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in...

Sponsor: Rigel PharmaceuticalsEnrolling: 162 locations
RECRUITINGPhase 1NCT05460507

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular...

Sponsor: Plus TherapeuticsEnrolling: 401 location
RECRUITINGNCT07411690

Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors

Cerebrospinal fluid is a clear fluid that surrounds and protects the brain. During surgery for brain tumors, neurosurgeons often need to open the covering of the brain (the dura)...

Sponsor: Medical University of WarsawEnrolling: 2001 location
RECRUITINGNCT06368310

FIH Clinical Investigation of Graphene Electrodes for Brain Mapping

The goal of this clinical investigation of a medical device is to test the safety of graphene based electrodes when used during surgery for resection of brain tumors. The main...

Sponsor: University of ManchesterEnrolling: 101 location
RECRUITINGNCT07547163

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy...

The study aims to assess the direct patient-reported perception (PROs) of individuals affected by IDH-mutant, grade 2 gliomas undergoing radiotherapy or pharmacological treatment...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 901 location
RECRUITINGNCT05990244

Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion

this study will investigate the relationship between tumor stiffness and adhesion in gliomas using MRE. By utilizing preoperative MRE and Intraoperative neuronavigation, followed...

Sponsor: Shengjing HospitalEnrolling: 1001 location
RECRUITINGPhase 1 / Phase 2NCT07416188

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often...

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)Enrolling: 401 location
RECRUITINGNCT05259605

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and...

Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments,...

Sponsor: European Organisation for Research and Treatment of Cancer - EORTCEnrolling: 165020 locations
RECRUITINGPhase 1NCT05538130

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced...

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with...

Sponsor: PfizerEnrolling: 12420 locations

Frequently Asked Questions

There are currently 10 clinical trials for Glioma, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Glioma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Glioma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.